Retinoblastoma Loss in Cancer: Casting a Wider Net.
Atish D ChoudhuryHimisha BeltranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Capturing both genomic and nongenomic mechanisms of retinoblastoma gene dysfunction has potential to improve risk stratification and patient selection for biomarker-driven therapy. A 186-gene expression signature is capable of identifying Rb loss across cancer types, providing a new framework for assessing Rb dysfunction based on transcriptome data.See related article by Chen et al., p. 4290.